Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-α-positive and -negative breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 3-5, 2009, Pages 182-188

  Lin, Hung Yun ^a   Sun, Mingzeng ^a   Lin, Cassie ^a   Tang, Heng Yuan ^a   London, David ^a   Shih, Ai ^a   Davis, Faith B ^a   Davis, Paul J ^a,b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Androgen; Breast cancer; Estrogen receptor; Integrin v 3

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; ARGINYLGLYCYLASPARTIC ACID; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; SMALL INTERFERING RNA; VITRONECTIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HORMONE ACTION; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANDROGENS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; FLUTAMIDE; HUMANS; INTEGRIN ALPHAVBETA3; OLIGOPEPTIDES; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING;

EID: 61349173908     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.12.010     Document Type: Article

References (40)

1. Simon J.A. J.A. Safety of estrogen/androgen regimens. J. Reprod. Med. 46 3 Suppl. (2001) 281-290
2. Labrie F., Luu-The V., Labrie C., Bélanger A., Simard J., Lin S.X., and Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24 (2003) 152-182
3. Somboonporn W., and Davis S.R. National Health and Medical Research Council, Testosterone effects on the breast: implications for testosterone therapy for women. Endo. Rev. 25 (2004) 374-388
4. Tworoger S.S., Missmer S.A., Barbieri R.L., Willett W.C., Colditz G.A., and Hankinson S.E. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J. Natl. Cancer Inst. 97 (2005) 595-602
5. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288 (2002) 321-333
6. Missmer S.A., Eliassen A.H., Barbieri R.L., and Hankinson S.E. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 96 (2004) 1856-1865
7. Cummings S.R., Lee J.S., Lui L.Y., Stone K., Ljung B.M., and Cauleys J.A. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1047-1051
8. Stanczyk F.Z., Lee J.S., and Santen R.J. Standardization of steroid hormone assays: why, how, and when?. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1713-1719
9. Sonne-Hansen K., and Lykkesfeldt A.E. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J. Steroid Biochem. Mol. Biol. 93 (2005) 25-34
10. Simpson E., Rubin G., Clyne C., Robertson K., O'Donnell L., Jones M., and Davis S. The role of local estrogen biosynthesis in males and females. Trends Endocrinol. Metab. 11 (2000) 184-188
11. Shufelt C.L., and Braunstein G.D. Testosterone and the breast. Menopause Int. 14 (2008) 117-122
12. Schover L.R. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?. Fertil. Steril. 90 (2008) 129-140
13. Toth-Fejel S., Cheek J., Calhoun K., Muller P., and Pommier R.F. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch. Surg. 139 (2004) 50-54
14. Yeh S., Hu Y.C., Wang P.H., Xie C., Xu Q., Tsai M.Y., Dong Z., Wang R.S., Lee T.H., and Chang C. Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J. Exp. Med. 198 2003 (2003) 1899-1908
15. Agoff S.N., Swanson P.E., Linden H., Hawes S.E., and Lawton T.J. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohisto-chemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120 (2003) 725-731
16. Bayer-Garner I.B., and Smoller B. Androgen receptors: a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site. Mod. Pathol. 13 2000 (2000) 119-122
17. Lin H.Y., Zhang S.L., West B.L., Tang H.-Y., Passaretti T., Davis F.B., and Davis P.J. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-beta1 DNA-binding domain: functional consequences of mutations at the docking site. Biochemistry 42 (2003) 7571-7579
18. Tang H.Y., Shih A., Cao H.J., Davis F.B., Davis P.J., and Lin H.Y. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 5 (2006) 2034-2042
19. Bergh J.J., Lin H.Y., Lansing L., Mohamed S.N., Davis F.B., Mousa S., and Davis P.J. Integrin αvβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146 (2005) 2864-2871
20. Davis F.B., Tang H.Y., Shih A., Keating T., Lansing L., Hercbergs A., Fenstermaker R.A., Mousa A., Mousa S.A., Davis P.J., and Lin H.Y. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 66 (2006) 7270-7275
21. Tang H.Y., Lin H.Y., Zhang S., Davis F.B., and Davis P.J. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145 (2004) 3265-3272
22. Lin H.Y., Lansing L., Merillon J.M., Davis F.B., Tang H.Y., Shih A., Vitrac X., Krisa S., Keating T., Cao H.J., Bergh J.J., and Davis P.J. Integrin αvβ3 contains a receptor site for resveratrol. FASEB J. 20 (2006) 1742-1744
23. Lin H.Y., Tang H.Y., Shih A., Keating T., Cao G., Davis P.J., and Davis F.B. Thyroxine induces MAPK activation and blocks resveratrol-induced apoptosis in human thyroid cancer cell lines. Steroids 72 (2007) 180-187
24. Lin H.Y., Tang H.Y., Keating T., Wu Y.H., Shih A., Hammond D., Sun M., Hercbergs A., Davis F.B., and Davis P.J. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin- and ERK-mediated. Carcinogenesis 29 (2008) 62-69
25. Birrell S.N., Bentel J.M., Hickey T.E., Ricciardelli C., Weger M.A., Horsfall D.J., and Tilley W.D. Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 52 (1995) 459-467
26. Buchanan G., Birrell S.N., Peters A.A., Bianco-Miotto T., Ramsay K., Cops E.J., Yang M., Harris J.M., Simila H.A., Moore N.L., Bentel J.M., Ricciardelli C., Horsfall D.J., Butler L.M., and Tilley W.D. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 65 (2005) 8487-8496
27. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mesquita H.B., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils C.H., Gonzalez C.A., Gurrea A.B., Critselis E., Khaw K.T., Krogh V., Lahmann P.H., Nagel G., Olsen A., Onland-Moret N.C., Overvad K., Palli D., Panico S., Peeters P., Quirós J.R., Roddam A., Thiebaut A., Tjønneland A., Chirlaque M.D., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., and Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 97 (2005) 755-765
28. Onland-Moret N.C., Kaaks R., van Noord P.A., Rinaldi S., Key T., Grobbee D.E., and Peeters P.H. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br. J. Cancer 88 (2003) 1394-1399
29. Colditz G.A. Epidemiology and prevention of breast cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 768-772
30. Wang D.Y., Allen D.S., De Stavola B.L., Fentiman I.S., Brussen J., Bulbrook R.D., Thomas B.S., Hayward J.L., and Reed M.J. Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br. J. Cancer 82 (2000) 1577-1584
31. Seymour-Munn K., and Adams J. Estrogenic effects of 5-androstene-3β, 17β-diol at physiological concentrations and its possible implication in the etiology of breast cancer. Endocrinology 112 (1983) 486-491
32. Ebeling P., and Koivisto V.A. Physiological importance of dehydroepiandrosterone. Lancet 343 (1994) 1479-1481
33. Cauley J.A., Gutai J.P., Kuller L.H., LeDonne D., and Powell J.G. The epidemiology of serum sex hormones in postmenopausal women. Am. J. Epidemiol. 129 (1989) 1120-1131
34. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol. 4 (2008) 15-21
35. Garreau J.R., Muller P., Pommier R., and Pommier S. Transgenic introduction of androgen receptor into estrogen-receptor-, progesterone-receptor-, and androgen-receptor-negative breast cancer cells renders them responsive to hormonal manipulation. Am. J. Surg. 191 (2006) 576-580
36. Birrell S.N., Butler L.M., Harris J.M., Buchanan G., and Tilley W.D. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 21 (2007) 2285-2293
37. Razandi M., Pedram A., and Levin E.R. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol. Endocrinol. 14 (2000) 1434-1447
38. Russell K.S., Haynes M.P., Sinha D., Clerisme E., and Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5930-5935
39. Pedchenko V., Zent R., and Hudson B.G. αvβ3 and αvβ5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the α3 chain of type IV collagen: implication for the mechanism of endothelial cell adhesion. J. Biol. Chem. 279 (2004) 2772-2780
40. Adair B.D., Xiong J.P., Maddock C., Goodman S.L., Arnaout M.A., and Yeager M. Three-dimensional EM structure of the ectodomain of integrin αvβ3 in a complex with fibronectin. J. Cell Biol. 168 (2005) 1109-1118